Glucocorticoid Antagonists in Heavy Drinkers: Effects on fMRI Connectivity, Withdrawal and Drinking

Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

In alcohol use disorder (AUD) and matched healthy control (HC) men and women, the proposed research examines the effects of MIFE, with demonstrated preclinical effects on drinking-related behaviors, compared with placebo on a breadth of alcohol-related measures. All subjects will be randomized to daily MIFE or placebo. Before and during medication, AUD and HC subjects undergo fMRI scanning measuring resting-state functional connectivity and alcohol cue-induced brain activation focused on brain reward and stress pathways. All subjects are admitted to the Clinical Research Unit; AUD subjects undergo supervised alcohol withdrawal with daily measurements of alcohol craving and symptom severity. Using validated human laboratory procedures in AUD subjects, this study will examine the effects of stress on motivation to drink and alcohol sensitivity/reward as a function of GR antagonism.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 55
Healthy Volunteers: t
View:

• Nontreatment seeking AUD volunteers

• English speaking

• healthy

• Not pregnant or nursing

Locations
United States
Maryland
Integrated Program for Substance Abuse Research
Baltimore
Time Frame
Start Date: 2017-09-26
Completion Date: 2024-01-31
Participants
Target number of participants: 65
Treatments
Active_comparator: Mifepristone
Mifepristone is a high affinity antagonist of the glucocorticoid receptor (GR). It is FDA approved to treatment hyperglycemia caused by high cortisol levels in adults with endogenous Cushing's syndrome.
Placebo_comparator: Placebo - Cap
This is an inactive compound which appears physically identical to active medication.
Authors
Sponsors
Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Leads: Johns Hopkins University

This content was sourced from clinicaltrials.gov